Glofitamab monotherapy retreatment in patients with heavily pre-treated relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL): Results from a phase I/II study

被引：0
|
作者：
Bartlett, Nancy L.
Dickinson, Michael
Hutchings, Martin
Carlo-Stella, Carmelo
Wu, Shang-Ju
Leppa, Sirpa
Trneny, Marek
Corradini, Paolo
Offner, Fritz
Mulvihill, Estefania
Bottos, Alessia
Chohan, Saibah
Baumlin, Pauline
Relf, James
Lundberg, Linda
Bachy, Emmanuel
机构：
[1] Washington Univ, St Louis, MO USA
[2] Peter MacCallum Canc Ctr, Melbourne, Australia
[3] Rigshosp, Copenhagen, Denmark
[4] Univ Copenhagen, Copenhagen, Denmark
[5] Humanitas Univ, Milan, Italy
[6] IRCCS Humanitas Res Hosp, Milan, Italy
[7] Natl Taiwan Univ Hosp, Taipei, Taiwan
[8] Univ Helsinki, Helsinki, Finland
[9] Helsinki Univ Hosp, Ctr Comprehens Canc, Helsinki, Finland
[10] Charles Univ Prague, Prague, Czech Republic
[11] Univ Milan, Milan, Italy
[12] Ist Nazl Tumori, Fdn Ist Ricovero & Cura & Carattere Sci IRCCS, Milan, Italy
[13] Univ Ziekenhuis, Ghent, Belgium
[14] F Hoffmann La Roche Ltd, Basel, Switzerland
[15] Hoffmann La Roche Ltd, Mississauga, ON, Canada
[16] La Roche Prod Ltd, Welwyn Garden City, Herts, England
[17] Hosp Civils Lyon, Pierre Benite, France
[18] Univ Claude Bernard, Pierre Benite, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7020
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Glofitamab monotherapy induces high complete response rates in patients with heavily pretreated Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL)
    Dreyling, M.
    Phillips, T.
    Dickinson, M.
    Morschhauser, F.
    Bachy, E.
    Crump, M.
    Trneny, M.
    Bartlett, N. L.
    Zaucha, J.
    Wrobel, T.
    Offner, F.
    Humphrey, K.
    Lundberg, L.
    Relf, J.
    de L'Etang, Filezac A.
    Carlile, D.
    Byrne, B.
    Qayum, N.
    Carlo-Stella, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 23 - 24
  • [42] Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin (PoV) or pinatuzumab vedotin (PiV) plus rituximab (RTX) in patients (Pts) with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL).
    Morschhauser, Franck
    Flinn, Ian
    Advani, Ranjana H.
    Sehn, Laurie Helen
    Kolibaba, Kathryn S.
    Press, Oliver W.
    Salles, Gilles A.
    Diefenbach, Catherine S. Magid
    Tilly, Herve
    Assouline, Sarit E.
    Chen, Andrew Tzong-Yow
    Dreyling, Martin H.
    Hagenbeek, Anton
    Zinzani, Pier Luigi
    Cheson, Bruce D.
    Yalamanchili, Sreenivasu
    Lu, Dan
    Chai, Akiko
    Chu, Yu-Waye
    Sharman, Jeff Porter
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [43] Phase I study of CC-90010, a reversible, oral BET inhibitor in patients (Pts) with advanced solid tumors (STs) and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)
    Moreno, V.
    Brana, I.
    Sepulveda Sanchez, J. M.
    Vieito Villar, M.
    Hernandez Guerrero, T.
    Doger, B.
    Saavedra, O.
    Pinto, A.
    Carlo Stella, C.
    Italiano, A.
    Michot, J-M.
    Musuraca, G.
    Sarmiento, R.
    De Alvaro, J.
    Zuraek, M.
    Sanchez-Perez, T.
    Aronchik, I.
    Filvaroff, E.
    Hanna, B.
    Nikolova, Z.
    ANNALS OF ONCOLOGY, 2020, 31 : S5 - S5
  • [44] Phase II study of oxaliplatin in patients with relapsed or refractory non-Hodgkin's lymphoma: Final results.
    Oki, Y
    McLauhlin, P
    Pro, B
    Hagemeister, FH
    Bleyer, A
    Loyer, E
    Younes, A
    BLOOD, 2004, 104 (11) : 684A - 684A
  • [45] Subcutaneous mosunetuzumab is active with a manageable safety profile in patients (pts) with Relapsed/Refractory (R/R) B-cell non-Hodgkin Lymphomas (B-NHL): updated results from a Phase I/II study
    von Tresckow, B.
    Budde, L. E.
    Bartlett, N. L.
    Giri, P.
    Schuster, S. J.
    Assouline, S.
    Yoon, S. S.
    Fay, K.
    Matasar, M.
    Gutierrez, N. C.
    Marlton, P.
    Dreyling, M.
    Yoon, D. H.
    Hess, G.
    Radford, J.
    Wiebking, V.
    Yin, S.
    Cybulski, E.
    Turner, D. C.
    Huang, H.
    Zhou, M.
    Penuel, E.
    Wei, M. C.
    Sehn, L. H.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 206 - 207
  • [46] Brentuximab vedotin for relapsed or refractory non-Hodgkin lymphoma: Preliminary results from a phase II study.
    Advani, Ranjana
    Oki, Yasuhiro
    Shustov, Andrei R.
    Grove, Laurie E.
    Bartlett, Nancy
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [47] Results of a multi-center, phase II study of Elsamitrucin (SPI-28090) in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL).
    Foon, K
    Allen, S
    Sen, K
    Mohrbacher, A
    Sanani, S
    Lenaz, L
    Rosales, R
    BLOOD, 2005, 106 (11) : 265B - 266B
  • [48] Results of a phase I/II trial of pixantrone in combination with fludarabine, dexamethasone, and rituximab in the treatment of patients with relapsed/refractory indolent non-Hodgkin's lymphoma (NHL).
    Fayad, Luis
    Liebmann, James
    Modiano, Manuel
    Cohen, Gary
    Pro, Barbara
    Romaguera, Jorge
    Stromatt, Scott
    BLOOD, 2006, 108 (11) : 781A - 781A
  • [49] A phase I study of rituximab and buparlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma
    Bond, David A.
    Huang, Ying
    Christian, Beth A.
    Jaglowski, Samantha
    Benson, Don
    Alinari, Lapo
    Baiocchi, Robert A.
    Cohen, Jonathon B.
    Blum, Kristie A.
    Maddocks, Kami J.
    LEUKEMIA & LYMPHOMA, 2022, 63 (07) : 1750 - 1753
  • [50] Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma
    Ribrag, Vincent
    Caballero, Dolores
    Ferme, Christophe
    Zucca, Emanuele
    Arranz, Reyes
    Briones, Javier
    Gisselbrecht, Christian
    Salles, Gilles
    Gianni, Alessandro M.
    Gomez, Henry
    Kahatt, Carmen
    Corrado, Claudia
    Szyldergemajn, Sergio
    Extremera, Sonia
    de Miguel, Bernardo
    Cullell-Young, Martin
    Cavalli, Franco
    HAEMATOLOGICA, 2013, 98 (03) : 357 - 363
12345